Bo Xu1, Oziemski Peter. 1. Intensive Care Unit, Peter MacCallum Cancer Institute, , East Melbourne, Victoria.
Abstract
BACKGROUND: The ' Surviving Sepsis' Campaign guidelines recommend the use of dopamine or noradrenaline as the first vasopressor in septic shock. However, information that guides clinicians in choosing between dopamine and noradrenaline as the first vasopressor in patients with septic shock is limited. OBJECTIVE: This article presents a review of the literature regarding the use of dopamine versus noradrenaline in patients with septic shock. RESULTS: Two randomised controlled trials (RCT) and two large prospective cohort studies were analysed. RCT data showed dopamine was associated with increased arrhythmic events. One cohort study found dopamine was associated with higher 30-day mortality. The other cohort study found noradrenaline was associated with higher 28-day mortality. DISCUSSION: Data on the use of dopamine versus noradrenaline in patients with septic shock is limited. Following the recent SOAP II study, there is now strong evidence that the use of dopamine in septic shock is associated with significantly more cardiovascular adverse events, compared to noradrenaline. CONCLUSION: Noradrenaline should be used as the initial vasopressor in septic shock to avoid the arrhythmic events associated with dopamine.
BACKGROUND: The ' Surviving Sepsis' Campaign guidelines recommend the use of dopamine or noradrenaline as the first vasopressor in septic shock. However, information that guides clinicians in choosing between dopamine and noradrenaline as the first vasopressor in patients with septic shock is limited. OBJECTIVE: This article presents a review of the literature regarding the use of dopamine versus noradrenaline in patients with septic shock. RESULTS: Two randomised controlled trials (RCT) and two large prospective cohort studies were analysed. RCT data showed dopamine was associated with increased arrhythmic events. One cohort study found dopamine was associated with higher 30-day mortality. The other cohort study found noradrenaline was associated with higher 28-day mortality. DISCUSSION: Data on the use of dopamine versus noradrenaline in patients with septic shock is limited. Following the recent SOAP II study, there is now strong evidence that the use of dopamine in septic shock is associated with significantly more cardiovascular adverse events, compared to noradrenaline. CONCLUSION:Noradrenaline should be used as the initial vasopressor in septic shock to avoid the arrhythmic events associated with dopamine.
Authors: Yasser Sakr; Konrad Reinhart; Jean-Louis Vincent; Charles L Sprung; Rui Moreno; V Marco Ranieri; Daniel De Backer; Didier Payen Journal: Crit Care Med Date: 2006-03 Impact factor: 7.598
Authors: Daniel De Backer; Patrick Biston; Jacques Devriendt; Christian Madl; Didier Chochrad; Cesar Aldecoa; Alexandre Brasseur; Pierre Defrance; Philippe Gottignies; Jean-Louis Vincent Journal: N Engl J Med Date: 2010-03-04 Impact factor: 91.245
Authors: R Phillip Dellinger; Mitchell M Levy; Jean M Carlet; Julian Bion; Margaret M Parker; Roman Jaeschke; Konrad Reinhart; Derek C Angus; Christian Brun-Buisson; Richard Beale; Thierry Calandra; Jean-Francois Dhainaut; Herwig Gerlach; Maurene Harvey; John J Marini; John Marshall; Marco Ranieri; Graham Ramsay; Jonathan Sevransky; B Taylor Thompson; Sean Townsend; Jeffrey S Vender; Janice L Zimmerman; Jean-Louis Vincent Journal: Crit Care Med Date: 2008-01 Impact factor: 7.598
Authors: Gourang P Patel; Jaime Simon Grahe; Mathew Sperry; Sunit Singla; Ellen Elpern; Omar Lateef; Robert A Balk Journal: Shock Date: 2010-04 Impact factor: 3.454